(Q36847276)

16 August 2017

1 reference

title

Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

0 references

Pander J

1

1 reference

16 August 2017

Gelderblom H

series ordinal

2

1 reference

16 August 2017

Guchelaar HJ

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

1 reference

16 August 2017

8

1 reference

16 August 2017

9

1 reference

16 August 2017

1197-1210

1 reference

Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Mistaken identity: misclassification of TPMT phenotype following blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

CYP2D6 genotype and tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

What makes a good genetic association study?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Thiopurine methyltransferase alleles in British and Ghanaian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.9.1197

10.1517/14656566.8.9.1197

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference